Get the Stockscreener App
12.50
1.60%
0.010
Tenax Therapeutics Inc stock is traded at $12.50, with a volume of 243.28K.
It is up +1.60% in the last 24 hours and down -14.72% over the past month.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
See More
Previous Close:
$12.49
Open:
$12.54
24h Volume:
243.28K
Relative Volume:
0.59
Market Cap:
$322.19M
Revenue:
-
Net Income/Loss:
$-52.60M
P/E Ratio:
-9.3556
EPS:
-1.3361
Net Cash Flow:
$-35.80M
1W Performance:
-0.70%
1M Performance:
-14.72%
6M Performance:
+83.38%
1Y Performance:
+136.75%
1-Day Range:
$12.10
$12.77
1-Week Range:
$12.10
$13.73
52-Week Range:
$5.34
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
12.50 | 321.94M | 0 | -52.60M | -35.80M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
427.16 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.40 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
810.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.94 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.78 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-25 | Initiated | Piper Sandler | Overweight |
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Tenax Therapeutics names Timothy Healey as chief commercial officer By Investing.com - Investing.com Australia
Invus affiliates disclose 2.1% stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax brings in drug launch veteran Timothy Healey to prep TNX-103 - Stock Titan
Tenax Therapeutics, Inc. Appoints Timothy Healey as Chief Commercial Officer, Effective May 4, 2026 - marketscreener.com
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics appoints Thomas Staab as chief financial officer - MSN
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans - Sahm
Discipline and Rules-Based Execution in TENX Response - Stock Traders Daily
How do interest rates affect Tenax Therapeutics (TENX) stock | Q4 2025: Profit Exceeds ViewsSpin Off - Newser
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving AverageHere's What Happened - MarketBeat
Tenax Therapeutics names new CFO - MSN
Tenax Therapeutics names Thomas Staab as chief financial officer By Investing.com - Investing.com India
Tenax Therapeutics (TENX) Stock Movers | Q4 2025: EPS Tops ViewsStock Analysis Community - UBND thành phố Hải Phòng
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth - Yahoo Finance
Tenax Therapeutics Names New CFO to Support Growth - TipRanks
Tenax Therapeutics names Thomas Staab as chief financial officer - Investing.com
[ARS] TENAX THERAPEUTICS, INC. SEC Filing - Stock Titan
Tenax Therapeutics (NASDAQ: TENX) 2026 proxy details director slate, auditor vote - Stock Titan
Tenax Therapeutics (NASDAQ: TENX) hires new CFO Thomas Staab with equity grants - Stock Titan
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer - The Manila Times
Tenax Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Tenax Therapeutics (TENX) Stock Index Trade (Ticks Lower) 2026-04-20Retail Flow - Cổng thông tin điện tử Tỉnh Sơn La
Behavioral Patterns of TENX and Institutional Flows - Stock Traders Daily
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Panic Selling: Is Tenax Therapeutics Inc forming a double bottom2026 Institutional & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Is Tenax Therapeutics (TENX) Stock Priced Correctly | Price at $14.27, Down 1.11%Wall Street Picks - Newser
CEO Moves: Is Tenax Therapeutics Inc forming a double bottom2026 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX) and Ligand Pharma (LGND) - The Globe and Mail
If You Invested $1,000 in Tenax Therapeutics Inc (TENX) - Stock Titan
TENX Options Volatility — NASDAQ:TENX - TradingView
TENX Options Chain — NASDAQ:TENX - TradingView
TENAX Therapeutics (NASDAQ: TENX) — Morgan Stanley reports 3.5%/3.4% positions - Stock Titan
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Is Tenax Therapeutics (TENX) Stock Suitable for 2026 | Price at $14.59, Down 1.95%Correlation Analysis - Cổng thông tin điện tử tỉnh Lào Cai
(TENX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
TENX Should I Buy - Intellectia AI
[EFFECT] TENAX THERAPEUTICS, INC. SEC Filing - Stock Titan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Volume Summary: What are Tenax Therapeutics Incs recent SEC filings showingOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView — Track All Markets
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tenax Therapeutics Inc Stock (TENX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):